By utilizing antibodies that bind to target proteins, IHC provides valuable insights into cellular structures, disease markers, and molecular interactions. This technique bridges the gap between histology and molecular biology, making it essential in both clinical diagnostics and research. It enables the study of various cellular components, such as proteins, hormones, and infectious agents, aiding pathology by revealing tissue architecture, identifying disease markers, and enhancing our understanding of cellular interactions¹.

A key advantage of IHC over immunofluorescence-based techniques is its ability to visualize tissue morphology around specific antigens. The results are reported semi-quantitatively, carrying both diagnostic and prognostic significance.

IHC is an important technique for disease detection, classification, and management across various fields, including surgical pathology, cytopathology, and research. It is used for identifying neoplasms, confirming infectious agents, diagnosing neurodegenerative diseases and muscle disorders, and analyzing autopsy samples, such as brain injuries. In forensic medicine, IHC aids in dating skin injuries and identifying asphyxia. Its ability to determine antigen distribution and analyze cellular morphology makes it indispensable for both clinical and research applications¹.

Importance of IHC in medical and research fields

• Accurate diagnosis, prognosis, and monitoring of treatment: IHC staining helps distinguish between different types of cancer, predict disease progression, and monitor treatment efficacy. For example, human epidermal growth factor receptor 2 (HER2) staining in breast cancer tissue determines the suitability of targeted therapies². It has also been used to identify and detect pathogens causing infectious diseases, including bacteria (Yersinia pestis, Treponema pallidum, and Coxiella burnetiid) and viruses (HIV, herpes virus). IHC has also been used for other diseases, such as Alzheimer’s disease and Parkinson’s disease, and autoimmune diseases, such as autoimmune bullous diseases and autoimmune skin blistering diseases.
• Research in disease mechanisms and biomarker discovery: IHC staining facilitates the identification of novel biomarkers, enabling us to better understand disease pathogenesis³. By studying protein expression patterns, researchers can uncover potential therapeutic targets and develop more effective treatments.
• Supports personalized medicine and targeted therapies: IHC staining informs personalized treatment strategies by identifying specific molecular profiles⁴. This targeted approach ensures patients receive the most effective therapies, improving treatment outcomes and reducing adverse reactions.

Principles of IHC staining

IHC combines the principles of immunology and histology, allowing researchers and clinicians to study the distribution and localization of proteins within cells and tissues, as well as cellular morphology and tissue structure. IHC relies on the specificity of antibodies for their target antigens.

Counterstaining is commonly performed as part of the IHC procedure to stain specific organelles or cell compartments to add color contrast and augment the localization of the target being studied. Counterstaining in IHC presents advantages such as improved visualization, studying tissue structure and morphology, cellular make-up, and orientation, and assessing the cells or structures that stain. Hence, counterstaining is routinely performed in pathology labs.

Hematoxylin is often employed as an IHC counterstain as the relative contrast produced between the blue color of hematoxylin and brown/red chromogens like 3-amino-9-ethyl-carbazole (AEC) and 3,3’-diaminobenzidine (DAB). Additionally, researchers recommend the use of hematoxylin and eosin (H&E) staining for counterstaining (instead of only hematoxylin counterstaining) for augmented precision in research and diagnosis.

Antigen-antibody interactions in IHC

At its core, IHC staining relies on the specific binding between antibodies and antigens1. The specific region on an antigen recognized by an antibody is known as an epitope. There are two main types of epitopes:

• Linear epitopes: Continuous amino acid sequences within a protein.
• Conformational epitopes: Three-dimensional structures formed by amino acid interactions⁵.

Antibodies are used to target and detect specific antigens within tissue samples. This antigen-antibody interaction is based on complementary binding. Understanding epitope recognition is important for selecting optimal antibodies and interpreting IHC staining results.

Types of IHC staining detection methods

Various detection methods are employed to visualize antigen-antibody interactions. These methods differ in sensitivity, specificity, and practical applications. The principle of IHC relies on the binding of a specific antibody to the target antigen within a tissue. The resulting antigen-antibody complex is then visualized using various detection techniques.

The selection of an antibody entails understanding the target and validating the antibody; polyclonal antibodies recognize multiple epitopes of an antigen, offering greater sensitivity for low-abundance targets, while monoclonal antibodies offer better reproducibility and specificity.

To visualize the antigen-antibody reaction, antibodies are tagged with enzymes such as horseradish peroxidase (HRP) or alkaline phosphatase (AP). When specific substrates are applied, a colored product develops. Additionally, various stains can be used in IHC depending on the intended application, as summarized below:

• Diaminobenzidine (DAB): Forms a brown precipitate when oxidized by hydrogen peroxide in a reaction catalyzed by horseradish peroxidase (HRP). DAB is used to visualize antibody binding with HRP-labeled antibodies, where the intensity and distribution of the DAB staining help deduce the distribution of the target protein in the sample. DAB has the advantage of being stable for many years and is also heat stable.
• H&E: This is a well-known approach where the hematoxylin stains nuclei (nucleic acids and other cell components like keratohyalin granules) blue and eosin stains cytoplasmic proteins red/pink. Hematoxylin and eosin are used to visualize tissue structures and identify morphological changes in diseases.
• 3-Amino-9-ethylcarbazole (AEC): Produces a red color and is used as an alternative to DAB, especially in cases where a contrasting color is needed, for example, contrasts well with blue in double staining or if DAB gives a high background.
• Fast red: Liquid fast red is a chromogen that produces a red color in the presence of alkaline phosphatase, finding use in alkaline phosphatase-based detection systems.
• Methyl green: Stains nuclei (DNA) green or blue and is often used as a counterstain in IHC.

Direct vs. indirect IHC staining methods

Direct methods involve labeling primary antibodies with detection molecules, whereas indirect methods employ secondary antibodies to detect primary antibodies¹. Indirect methods are more sensitive but require additional steps.

Polymer-based detection

This method utilizes polymer chains conjugated with enzymes or fluorescent tags to amplify detection signals. Polymer-based detection offers enhanced sensitivity and reduced background noise⁷.

IHC staining procedure

Optimization of the IHC staining procedure helps in providing reliable and accurate results. This section outlines a step-by-step process highlighting key considerations and techniques.

Sample preparation

The first step in IHC is sample preparation, which significantly influences the quality and reliability of staining results. The process involves several key steps, each designed to preserve tissue morphology and ensure optimal antigen accessibility for antibody binding.

• Tissue collection: Involves the careful collection of tissue samples, which are through surgical procedures or biopsies. It is essential to handle the specimens gently to preserve antigenicity and morphology.
• Fixation: Preserves tissue structure and prevents degradation by cross-linking proteins. Common fixatives include formalin fixation and paraffin embedding (FFPE), which stabilize tissues⁸.
  However, it is essential to note that fixation methods can affect antigen retrieval and epitope accessibility. For example, FFPE is widely used for its ability to maintain tissue architecture, but it can mask epitopes, requiring additional antigen retrieval steps.
  Tissues are typically fixed for 24 hours at room temperature, although the time may vary based on tissue type and size. Alternative fixation methods, like frozen sectioning, may be employed for specific applications⁹.
• Dehydration: After fixation, tissues undergo dehydration using a series of increasing concentrations of ethanol (typically from 70% to 100%). This step removes water from the tissue, preparing it for embedding in paraffin. A clearing agent such as xylene is used to remove ethanol from the tissue. This step is essential as it makes the tissue compatible with paraffin.
• Embedding: Tissues are infiltrated with molten paraffin wax at approximately 60°C and then allowed to harden overnight. This process provides structural support for thin sectioning.
• Frozen sectioning: Alternatively, tissues can be frozen using liquid nitrogen or dry ice for immediate sectioning without the need for embedding in paraffin.
  Sectioning: Paraffin-embedded tissues are sliced into thin sections (typically 4-5 micrometers thick) using a microtome. Frozen sections can be cut using a cryostat.
• Deparaffinization and rehydration: After sectioning, deparaffinize and rehydrate tissue samples to remove paraffin wax and restore tissue hydration. This step is important for antigen retrieval and antibody penetration.

Solvents like xylene or toluene are used to dissolve paraffin, followed by a series of ethanol washes and rehydration in buffered solutions¹⁰.

Antigen retrieval techniques

Antigen retrieval is necessary for unmasking epitopes masked by fixation and embedding processes.

• Heat-induced epitope retrieval (HIER): HIER utilizes heat, pressure, and specific buffers (eg, citrate or Tris-EDTA) to break protein cross-links. This method is commonly used for FFPE samples and can be performed using a microwave, pressure cooker, or steamer¹¹.
• Enzymatic retrieval methods: Enzymatic retrieval methods employ enzymes (eg, proteinase K, trypsin) to break protein bonds¹². These methods are often used for samples with high collagen content or when HIER is ineffective.

Blocking techniques

Blocking is essential to reduce non-specific binding and background staining.

Endogenous enzyme blocking

Endogenous enzyme blocking inhibits endogenous enzymes (eg, peroxidase, alkaline phosphatase) to prevent false positives¹³. Specific inhibitors or blocking agents are used to minimize non-specific enzyme activity.

Protein blocking

Protein blocking uses proteins (eg, serum BSA) or detergents to block non-specific binding sites. This step helps reduce background staining and ensures specific antigen detection¹⁴.

Application of primary and secondary antibodies

Selecting appropriate antibodies is essential for specific antigen detection. Researchers evaluate factors such as antibody specificity, sensitivity, and optimal dilution to ensure reliable results. Amplification systems, such as the avidin-biotin complex, are employed to enhance signal sensitivity and improve detection efficiency¹⁵.

Detection and visualization techniques

• Chromogenic detection: Chromogenic detection uses enzymes to convert substrates into colored precipitates. It utilizes enzymes (eg, HRP) and substrates (eg, DAB) to produce a colored precipitate¹³. This method is widely used for bright field microscopy⁶.
• Fluorescent detection: Fluorescent detection utilizes fluorescent tags to emit light. It employs fluorescent dyes or tags to visualize antigens, such as fluorescein isothiocyanate (FITC) labeling of CD20 antibodies for lymphocyte detection¹⁶.

Counterstaining and mounting

The nuclear counterstains (eg, Hematoxylin) are applied to provide contrast and context¹⁷. Samples are then mounted and prepared for microscopic analysis.

Experimental approaches for IHC

Various IHC staining techniques are employed to visualize and analyze antigen-antibody interactions. These techniques can be categorized into several types, each with its advantages and applications.

Single vs multiplex IHC staining

Single IHC staining is used to detect a single antigen or protein in a tissue sample, providing valuable information on protein expression and localization. This technique is essential for identifying specific biomarkers, understanding protein function, and diagnosing diseases.

In contrast, multiplex IHC staining allows for the detection of multiple antigens simultaneously, offering insights into protein interactions, cell signaling pathways, and tissue heterogeneity. Multiplexing can be achieved through sequential staining with multiple primary antibodies, utilization of different fluorochromes or chromogens, and application of tyramide signal amplification (TSA) or other signal enhancement methods¹⁸.

Automated vs manual IHC staining

IHC staining can be performed manually or using automated systems. Manual staining offers flexibility and control but can be time-consuming and prone to human error. Automated staining systems provide consistency and reproducibility, increase throughput, and reduce labor and reagent costs¹⁹.

Advanced techniques in IHC

• Multiplexing for enhanced detection: Multiplexing combines multiple antibodies and detection methods to visualize complex tissue biology. By simultaneously detecting multiple antigens, researchers can study protein co-expression, cellular crosstalk, and tumor microenvironments²⁰.
  This technique has significantly enhanced our understanding of disease mechanisms and biomarker discovery.
• Digital pathology and image analysis: Digital pathology and image analysis utilize digital imaging and computational tools to analyze IHC-stained slides, extract quantitative data, and identify patterns²¹.
  This enables objective and reproducible analysis, high-throughput image analysis, and data integration with other omics technologies.
• Quantification using machine learning techniques: Quantification using machine learning techniques applies algorithms to analyze IHC data, identify biomarkers, and predict disease outcomes²³.
  Leveraging machine learning enables the automation of image analysis, facilitates data-driven decision-making, and supports the development of personalized medicine approaches.

Troubleshooting in IHC staining

Researchers often encounter challenges during IHC staining that can impact the accuracy and reliability of results.

Addressing non-specific staining and background noise

Non-specific staining and background noise can significantly compromise IHC results. To address these issues, optimizing blocking conditions, such as using serum or non-specific IgG²⁴, and utilizing specificity-enhancing reagents like avidin-biotin complexes.

Selecting optimal primary antibody concentrations and implementing rigorous washing protocols also helps. For example, utilizing a blocking buffer with 5% normal serum can reduce non-specific binding. Additionally, secondary antibodies with minimal cross-reactivity are used to minimize background noise.

Optimizing antibody concentration and incubation times

Antibody concentration and incubation times impact IHC staining. These parameters can be optimized through titration experiments to determine optimal antibody concentrations²⁴.

Adjusting incubation times based on antigen expression levels and evaluating temperature and agitation effects on antibody binding are also essential. For example, a 1:500 dilution of primary antibody may be optimal for one antigen, while a 1:100 dilution is required for another. This will be dependent on the sensitivity and specificity of the antibody.

Improving signal intensity and detection

Weak signal intensity can hinder IHC analysis. Signal detection is enhanced using amplification methods such as tyramide signal amplification (TSA) and sensitive detection reagents like HRP-conjugated secondary antibodies ¹⁸.

Optimizing chromogen or fluorochrome selection is also important. For example, TSA can increase signal intensity up to 100-fold. Additionally, selecting the right enzyme-substrate combination can significantly impact signal intensity.

Common pitfalls in antibody selection

Selecting the right antibody is vital for successful IHC staining. Common pitfalls can be avoided by verifying antibody specificity using appropriate controls (for example, a sample known not to express the target) and ensuring antibody compatibility with sample fixation and processing²⁴.

Considering antibody cross-reactivity with non-target antigens is also essential. For example, using an antibody validated for western blot may not guarantee success in IHC. Careful evaluation of antibody characteristics ensures reliable and accurate IHC results.

Importance of controls in IHC

Controls are essential in IHC staining to validate the specificity and sensitivity of results. Controls are used to verify antibody performance, detect potential errors, and establish assay reproducibility. Proper controls allow you to distinguish between specific and non-specific staining, ensuring confidence in conclusions. Incorporating controls into your experimental setup minimizes the risk of false positives or false negatives, ensuring reliable and accurate results.

Types of controls in IHC staining

• Positive controls: Confirms antibody specificity and staining efficacy²⁵. Tissues or cells known to express the target antigen are used as positive controls. For example, tonsil tissue is often used as a positive control for CD20 staining, while human epidermal growth factor receptor 2 (HER2)-positive breast cancer breast cancer tissue serves as a positive control for HER2 breast tissue staining.
  Including positive controls verifies that the staining protocol is functioning correctly and that the antibody is specifically binding to the target antigen.
• Negative controls: Allows for the identification of any non-specific staining and background noise25. Tissues or cells lacking the target antigen or the omission of primary antibodies are used as negative controls. For example, triple-negative breast cancer may be used as a negative control when staining for estrogen receptor (ER), progesterone receptor (PR), or HER2.
  Omitting primary antibodies in a staining run also helps detect non-specific binding. These controls enable us to distinguish between specific and non-specific staining patterns.
• Isotype controls: Verifies antibody specificity and minimizes false positives²⁵. Antibodies of the same isotype as the primary antibody but targeting an unrelated antigen are used as isotype controls. For example, a mouse IgG1 antibody against an unrelated antigen can serve as an isotype control for a mouse IgG1 anti-CD20 antibody.
  Isotype controls help ensure that any observed staining is not due to non-specific antibody binding.
• Additional control types: Other control types include peptide-blocking controls, knockout controls, and recombinant protein controls. Peptide-blocking controls involve using synthetic peptides to block antibody binding, while knockout controls utilize tissue or cells lacking the target gene.
  Recombinant protein controls employ purified proteins to validate antibody specificity. These additional controls provide further assurance of antibody specificity and staining accuracy²⁵.

Interpretation of IHC staining results

Staining patterns: When analyzing IHC staining results, various staining patterns are observed that provide unique information about protein localization and function. The three primary staining patterns are:

• Nuclear staining: Indicates protein expression within the cell nucleus, often associated with transcription factors or DNA-binding proteins, such as p53 and Ki-6726.
• Cytoplasmic staining: Reveals cytoplasmic protein expression, frequently linked to metabolic enzymes, structural proteins, or signaling molecules, for example, cytokeratin and actin, which both serve as structural proteins²⁷.
• Membranous staining: Identifies proteins expressed at the cell membrane, typically associated with receptors, transport proteins, or adhesion molecules, such as HER2 and CD20²⁸.

Quantification and scoring systems

Quantification and scoring systems are employed to objectively evaluate IHC staining intensity and distribution. These systems enable standardized staining assessment, comparison of results across samples and studies, and correlation with clinical or biochemical data²⁹.

• Immunoreactive score (0-12) is a composite score that measures the intensity and proportion of positive cells in a tissue sample. For example, assessing the expression of von Willebrand factor after an autogenous bone transplant.
• Allred score (0-8) combines the intensity and proportion of stained cells and is used for assessing the hormone receptor status.
• H-score (0-300) calculates staining intensity and the percentage of positive cells, and is commonly used for assessing cancerous tissue.
• Quick score (0-18) assesses intensity, proportion, and subcellular localization reported for estrogen receptors in breast cancer.
• Incidence method is a simple and qualitative approach that classifies as “affected” (presence of a marker) and “normal/unaffected” (absence of the marker). An example is the association of strong nuclear p53 staining and sebaceous carcinoma diagnosis.

Digital image analysis software enables quantitative assessment of staining intensity, area, and colocalization, providing a comprehensive understanding of protein expression.

Common applications of IHC staining

IHC staining has various applications in advancing the understanding of biology, disease mechanisms, and the development of therapeutics.

Cancer diagnosis and classification

IHC staining plays an important role in cancer diagnosis and classification. IHC is used to identify tumor biomarkers, determine cancer subtype and prognosis, detect cancer-specific antigens, and guide targeted therapy decisions. For example, IHC-based testing for PD-L1 expression helps identify non-small cell lung cancer patients responsive to immunotherapy. Additionally, HER2 IHC testing in breast cancer guides trastuzumab treatment³⁰.

In lymphoma diagnosis, IHC staining for CD20 helps distinguish between Hodgkin and non-Hodgkin lymphoma³². IHC detection of estrogen receptor (ER) and progesterone receptor (PR) in breast cancer informs hormone therapy decisions⁶.

Biomarker identification and personalized medicine

IHC staining enables biomarker discovery and validation, driving personalized medicine approaches. IHC is employed to identify predictive biomarkers for treatment response, develop companion diagnostics for targeted therapies, and investigate disease-specific protein expression patterns⁴.

For example, identifying BRCA1 and BRCA2 expressions in ovarian cancer helps predict response to poly (ADP-ribose) polymerase (PARP) inhibitors³³. Similarly, IHC-based tests for anaplastic lymphoma kinase (ALK) rearrangements in lung cancer guide crizotinib treatment³⁴. IHC staining also informs treatment decisions in melanoma, where programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression levels predict response to immunotherapy³⁵.

Research applications

In neurobiology, IHC is used to study neurotransmitter and receptor distribution, shedding light on neurological disorders like Alzheimer’s and Parkinson’s diseases³⁶. In immunology, IHC helps investigate immune cell infiltration and cytokine expression in autoimmune diseases like rheumatoid arthritis.

In stem cell biology, IHC staining can be used to detect stem cell markers and differentiation patterns, guiding regenerative medical strategies³⁷. For example, IHC staining of LGR5, a Wnt-associated stem cell marker, may be involved in liver cell regeneration and may serve as a potential biomarker for liver function recovery. IHC is also used to study disease models and mechanisms, evaluate therapeutic efficacy in preclinical trials, and investigate protein-protein interactions and signaling pathways³.

For example, IHC staining revealed the importance of beta-amyloid plaques in Alzheimer’s disease pathology38. Similarly, IHC analysis of immune cell infiltration in tumor microenvironments has illuminated cancer-immune interactions²⁰.

Innovations in IHC staining

• Automation and digital innovations: Advanced staining instruments facilitate high throughput staining with standardized protocols¹⁹. Digital slide scanning and image analysis software enable faster analysis, improved consistency, and enhanced image quality. Artificial intelligence (AI) and machine learning (ML) algorithms aid in image analysis, data extraction, and pattern recognition²³.
  The integration of automation and digital innovations has streamlined workflow, reduced manual errors, and increased productivity. For example, automated staining platforms allow the processing of multiple samples simultaneously, accelerating research and diagnostic workflows.
• Developments in antibody quality and standardization: High-quality antibodies are important for reliable IHC results. To address this, significant advancements in antibody validation methods, standardized antibody production, and quality control need to be addressed^24,39.
  Collaborative initiatives, such as the Human Protein Atlas and antibody registry, promote antibody standardization and sharing of information. These initiatives have improved antibody reliability, enabling more accurate and reproducible results. By adopting standardized antibodies, researchers can confidently compare results across studies and laboratories.
• Enhancing diagnostic accuracy and speed: Innovations in IHC staining have significantly improved diagnostic accuracy and speed. Multiplex IHC allows simultaneous detection of multiple biomarkers, enhancing cancer subtyping and biomarker identification¹⁸. Quantitative IHC enables precise protein expression analysis, predicting treatment response.
  Companion diagnostics have also emerged as an important application of IHC staining. Fast-track diagnostic assays for infectious diseases, such as Helicobacter pylori, demonstrate the potential of IHC staining in rapid disease diagnosis⁴⁰.

FAQs

What are the main steps involved in the IHC staining process?

The main steps in IHC staining are sample preparation (tissue collection, fixation, embedding, sectioning), deparaffinization, antigen retrieval, blocking, primary and secondary antibody application, detection and visualization, and counterstaining.

How does antigen retrieval improve the sensitivity of IHC?

Antigen retrieval unmasks epitopes masked by fixation and embedding, improving antibody binding and sensitivity. It breaks protein cross-links, exposing hidden epitopes and enhancing signal detection.

What is the importance of counterstaining in IHC?

Counterstaining helps to improve the detection of the target molecule or signal by providing a contrast to the chromogen used in IHC. It facilitates visualizing the localization of the target and can be used to help identify cell types. Further, nuclear counterstaining provides a contrast between the nucleus and the cytoplasm, cell membrane, and/or surrounding tissue, facilitating the study of the tissue and cellular morphology. Examples of such counterstains are hematoxylin and eosin, toluidine blue, methylene blue, and fast red.

What are counterstains that can be used in IHC?

Counterstains include Hematoxylin, which stains the nucleus and is commonly used, eosin, which stains cationic protein groups, methylene green for nuclear staining, methylene blue, which stains the nucleus and differentiates DNA and RNA, and toluidine blue, which stains the nucleus.

What are the different methods of antigen retrieval in IHC?

The two primary methods are heat-induced epitope retrieval (HIER) using heat and specific buffers, and enzymatic retrieval methods using enzymes like proteinase K or trypsin.

How do you choose the appropriate antibody concentration for IHC?

Choose the optimal antibody concentration by considering factors like antibody specificity, tissue type, and desired signal intensity. Perform titration experiments to optimize concentration. Additionally, refer to the antibody datasheet for guiding information on adequate dilutions.

What are the common pitfalls in the IHC staining procedure?

Common pitfalls include inadequate fixation, insufficient antigen retrieval, poor antibody specificity, inadequate blocking, and incorrect detection methods.

Does IHC staining require internal controls?

Yes, internal controls (eg, positive and negative controls) are essential to validate IHC results, and to ensure the specificity of the antibody.

What is the best blocking method in IHC?

The best blocking method depends on the specific application. Common methods include serum blocking, protein blocking (BSA), and detergent-based blocking. You should optimize blocking conditions for each antibody and tissue type, including the blocking reagent you use, the duration, and the temperature of the blocking step.

References

1. Schacht, V. & Kern, J. S. Basics of immunohistochemistry. Journal of investigative dermatology. 135, 1-4 (2015).
2. Potts, S. J., Krueger, J. S., Landis, N. D., et al. Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Laboratory investigation. 92, 1342-1357 (2012).
3. Oumarou Hama, H., Aboudharam, G., Barbieri, R., et al. Immunohistochemical diagnosis of human infectious diseases: a review. Diagnostic Pathology. 17, 17 (2022).
4. McCourt, C. M., Boyle, D., James, et al. Immunohistochemistry in the era of personalised medicine. Journal of clinical pathology. 66, 58-61(2013).
5. Forsström, B., Bisławska Axnäs, B., Rockberg, J., et al. Dissecting antibodies with regards to linear and conformational epitopes. Plos one. 10, (2015).
6. Zarrella, E. R., Coulter, M., Welsh, A. W., et al. Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement. Laboratory investigation. 96, 1016-1025 (2016).
7. Skaland, I., Nordhus, M., Gudlaugsson, E., et al. Evaluation of 5 different labeled polymer immunohistochemical detection systems. Applied Immunohistochemistry & Molecular Morphology. 18, 90-96 (2010).
8. Shi, S. R., Liu, C. & Taylor, C. R. Standardization of immunohistochemistry for formalin-fixed, paraffin-embedded tissue sections based on the antigen-retrieval technique: from experiments to hypothesis. Journal of histochemistry & cytochemistry. 55, 105-109 (2007).
9. Hofman, F. M. & Taylor, C. R. Immunohistochemistry. Current protocols in immunology. 103, 21-4 (2013).
10. Chen, C. Y., He, T., Mao, X. L., et al. A novel xylene substitute for histotechnology and histochemistry. Biotechnic & histochemistry. 85, 231-240 (2010).
11. Krenacs, L., Krenacs, T., Stelkovics, E., et al. Heat-induced antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections. Immunocytochemical methods and protocols. 103-119 (2010).
12. Ramos-Vara, J. A. Principles and methods of immunohistochemistry. Drug Safety Evaluation: methods and protocol., 115-128 (2017).
13. Krieg, R., & Halbhuber, K. J. Detection of endogenous and immuno-bound peroxidase—the status quo in histochemistry. Progress in histochemistry and cytochemistry. 45, 81-139 (2010).
14. Ramos-Vara, J. A. Technical aspects of immunohistochemistry. Veterinary pathology. 42, 405-426 (2005).
15. Davidoff, M. & Schulze, W. Combination of the peroxidase anti-peroxidase (PAP)-and avidin-biotin-peroxidase complex (ABC)-techniques: an amplification alternative in immunocytochemical staining. Histochemistry. 93, 531-536 (1990).
16. Beers, S. A., French, R. R., Chan, H. C., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood, the journal of the American society of hematology. 115, 5191-5201 (2010).
17. Dunstan, R. W., Wharton Jr, K. A., Quigley, C. et al. The use of immunohistochemistry for biomarker assessment - can it compete with other technologies. Toxicologic pathology. 39, 988-1002 (2011).
18. Harms, P. W., Frankel, T. L., Moutafi, M., et al. Multiplex immunohistochemistry and immunofluorescence: a practical update for pathologists. Modern pathology. 36, (2023).
19. Prichard, J. W. Overview of automated immunohistochemistry. Archives of pathology & laboratory medicine. 138, 1578-1582 (2014).
20. Viratham Pulsawatdi, A., Craig, S. G., Bingham, V., et al. A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment. Molecular oncology. 14, 2384-2402 (2020).
21. Van Eycke, Y. R., Allard, J., Salmon, I., et al. Image processing in digital pathology: an opportunity to solve inter-batch variability of immunohistochemical staining. Scientific reports. 7, (2017).
22. Woodhall, M., Mgbachi, V., Fox, H., et al. Utility of live cell-based assays for autoimmune neurology diagnostics. The journal of applied laboratory medicine. 7, 391-393 (2022).
23. Jackson, C. R., Sriharan, A. & Vaickus, L. J. A machine learning algorithm for simulating immunohistochemistry: development of SOX10 virtual IHC and evaluation on primarily melanocytic neoplasms. Modern Pathology. 33, 1638-1648 (2020).
24. Daneshtalab, N., Doré, J. J. & Smeda, J. S. Troubleshooting tissue specificity and antibody selection: Procedures in immunohistochemical studies. Journal of pharmacological and toxicological methods. 61, 127-135 (2010).
25. Hewitt, S. M., Baskin, D. G., Frevert, C. W., et al. Controls for immunohistochemistry: the Histochemical Society’s standards of practice for validation of immunohistochemical assays. Journal of histochemistry & cytochemistry. 62, 693-697 (2014).
26. Mateoiu, C., Pirici, A., & Bogdan, F. Immunohistochemical nuclear staining for p53, PCNA, Ki-67 and bcl-2 in different histologic variants of basal cell carcinoma. Romanian journal of morphology and embryology. 52, 315-9 (2011).
27. Tse, G. M. K., Tan, P. H., Lui, P. C. W., et al. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. Journal of clinical pathology. 60, 315-320 (2007).
28. Eiró, N., Pidal, I., Fernandez-Garcia, B., et al. Impact of CD68/ (CD3+ CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. Plos one. 7, (2012).
29. Rai, P. D., Vagha, S., Shukla, S. et al. Comparison of various scoring systems by immunohistochemistry for evaluating hormone receptors (Estrogen receptor and progesterone receptor) in carcinoma of breast. Journal of Datta Meghe institute of medical sciences university. 15, 202-208 (2020).
30. Phillips, T., Simmons, P., Inzunza, H. D., et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non–small cell lung cancer. Applied immunohistochemistry & molecular morphology. 23, 541-549 (2015).
31. Zaha, D. C. Significance of immunohistochemistry in breast cancer. World journal of clinical oncology. 5(3), 382 (2014).
32. Higgins, R. A., Blankenship, J. E. & Kinney, M. C. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Archives of pathology & laboratory medicine. 132, 441-461 (2008).
33. Teixeira, L. A. & Dos Reis, F. J. C. Immunohistochemistry for the detection of BRCA1 and BRCA2 proteins in patients with ovarian cancer: a systematic review. Journal of clinical pathology. 73, 191-196 (2020).
34. Shaw, A. T., Solomon, B. & Kenudson, M. M. Crizotinib and testing for ALK. Journal of the national comprehensive cancer network. 9, 1335-1341 (2011).
35. Rodig, S. J., Gusenleitner, D., Jackson, D. G., et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science translational medicine. 10, (2018).
36. Ünal, İ., Cansız, D., Beler, M., Sezer, Z., et al. Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson’s disease model in zebrafish; mechanism involving ketogenesis and autophagy. Brain research. 1820, (2023).
37. Khan, Z., Orr, A., Michalopoulos, G. K., et al. Immunohistochemical analysis of the stem cell marker LGR5 in pediatric liver disease. Pediatric and developmental pathology. 20, 16-27 (2017).
38. McGeer, P. L., Akiyama, H., Kawamata, T., et al. Immunohistochemical localization of beta‐amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy. Journal of neuroscience research. 31, 428-442 (1992).
39. Bordeaux, J., Welsh, A. W., Agarwal, S., et al. Antibody validation. Biotechniques. 48, 197-209 (2010).
40. Singh, D. K., Cole, J., Escobedo, R. A., et al. Animal models of COVID-19: Nonhuman primates. In SARS-CoV-2: methods and protocols. (2022).